Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-817399 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1: Placebo | PLACEBO_COMPARATOR | - |
| Arm 2: BMS-817399 (200 mg) | EXPERIMENTAL | - |
| Arm 3: BMS-817399 (400 mg) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Tablets, Oral, 0 mg, twice daily, 12 weeks |
| BMS-817399 | DRUG | Tablets, Oral, 200 mg, twice daily, 12 weeks |
Inclusion Criteria: * Male or female subjects, 18 years of age or older, with rheumatoid arthritis (RA) for at least 6 months prior to screening * Subjects must have a tender joint count of at least 6 (28 joint count), swollen joint count of at least 6 (28 joint count) at screening. All subjects mu...
Top 20 of 28 competitors
BMS-817399 is an investigational small molecule being developed for the treatment of moderate to severe rheumatoid arthritis. It is currently in Phase 2 clinical development and has not been approved by the FDA.
BMS-817399 is being developed by Bristol-Myers Squibb Company, which is publicly traded under the ticker symbol BMY on the New York Stock Exchange.
BMS-817399 is in Phase 2 clinical development. It is an investigational drug and has not yet received regulatory approval for any use.
BMS-817399 has one completed Phase 2 clinical trial, identified as NCT01404585. This was a proof-of-concept study in patients with moderate to severe rheumatoid arthritis, enrolling 123 participants across multiple countries.
Yes, the Phase 2 trial of BMS-817399 was a randomized, double-blind, placebo-controlled study. It enrolled 123 patients with moderate to severe rheumatoid arthritis and was conducted in the United States, Argentina, Mexico, Russia, South Africa, South Korea, and Spain.